Key Points
- Director Richard Ranieri sold 81,252 Xencor shares at an average of $39.25, receiving about $3.19 million. He retained 18,514 shares after reducing his position by 81.44%.
- Xencor reported quarterly EPS of $0.50, beating the consensus estimate of a $0.33 loss, while revenue of $116.52 million exceeded expectations and rose 453.3% year over year.
- Analysts gave Xencor a consensus “Moderate Buy” rating and an average price target of $42.22; targets ranged from $21 to $70.
Xencor, Inc. (NASDAQ:XNCR - Get Free Report) Director Richard Ranieri sold 81,252 shares of Xencor stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $39.25, for a total value of $3,189,141.00. Following the transaction, the director owned 18,514 shares of the company's stock, valued at $726,674.50. The trade was a 81.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Xencor Price Performance
Xencor stock opened at $38.13 on Friday. The business's fifty day simple moving average is $27.13 and its two-hundred day simple moving average is $17.98. Xencor, Inc. has a 12 month low of $10.38 and a 12 month high of $40.60.
Xencor (NASDAQ:XNCR - Get Free Report) last released its earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.83. Xencor had a negative return on equity of 21.28% and a negative net margin of 58.79%. The firm had revenue of $116.52 million for the quarter, compared to analysts' expectations of $63.00 million. During the same period in the prior year, the firm posted ($0.08) earnings per share. The company's quarterly revenue was up 453.3% on a year-over-year basis. Sell-side analysts predict that Xencor, Inc. will post -2.61 earnings per share for the current year.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on XNCR shares. Royal Bank Of Canada upped their price target on shares of Xencor from $20.00 to $43.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 27th. Raymond James Financial increased their price objective on shares of Xencor from $40.00 to $46.00 and gave the company a "strong-buy" rating in a research report on Tuesday, September 1st. Cantor Fitzgerald assumed coverage on shares of Xencor in a research note on Thursday, November 5th. They set an "overweight" rating and a $70.00 price objective for the company. Wells Fargo & Company lifted their target price on shares of Xencor from $30.00 to $44.00 and gave the stock an "overweight" rating in a report on Tuesday, October 27th. Finally, JPMorgan Chase & Co. upped their target price on shares of Xencor from $14.00 to $21.00 and gave the stock a "neutral" rating in a research note on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Xencor has a consensus rating of "Moderate Buy" and a consensus price target of $42.22.
Check Out Our Latest Research Report on Xencor
Institutional Trading of Xencor
Several institutional investors have recently added to or reduced their stakes in the business. Bessemer Group Inc. increased its holdings in shares of Xencor by 18.7% in the 3rd quarter. Bessemer Group Inc. now owns 1,791 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 282 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of Xencor in the second quarter worth $30,000. Allworth Financial LP purchased a new position in shares of Xencor in the second quarter worth $55,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Xencor in the third quarter worth $95,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Xencor by 15.5% during the third quarter. GAMMA Investing LLC now owns 4,269 shares of the biopharmaceutical company's stock valued at $107,000 after purchasing an additional 572 shares in the last quarter.
About Xencor
(
Get Free Report)
Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company's XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target. Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
